Novo Nordisk A/S vs T-Mobile Us Inc — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while T-Mobile Us Inc trades at $190.5 (market cap $211.72B). The key difference: Novo Nordisk A/S and T-Mobile Us Inc are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | TMUS | |
|---|---|---|
Market Cap | $220.53B | $211.72B |
Sector | Health | Media |
52-Week High | $71.70 | $259.01 |
52-Week Low | $35.29 | $167.65 |
Enterprise Value | $239.49B | $329.42B |
Dividend Yield | 3.63% | 2.09% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →